Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune response to vaccination with low-dose everolimus and/or BEZ235 in older adults
ACTRN12613001351707Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2013
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of everolimus, dactolisib and influenza vaccine in influenza (5 arms), sponsored by Novartis. Primary endpoints: Change in hemagglutination inhibition geometric mean titers 4 weeks after influenza vaccination and Safety and tolerability. Started Dec 2013; status: completed.
02
Drugs
everolimusdactolisibinfluenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on ACTRN12613001351707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613001351707.